Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBD

Background The identification of novel fecal biomarkers in inflammatory bowel disease (IBD) is hampered by the complexity of the human fecal proteome. On the other hand, in experimental mouse models there is probably less variation. We investigated the fecal protein content in mice to identify possible biomarkers and pathogenic mechanisms. Methods Fecal samples were collected at onset of inflammation in Galphai2-/- mice, a well-described spontaneous model of chronic colitis, and from healthy littermates. The fecal proteome was analyzed by two-dimensional electrophoresis and quantitative mass spectrometry and results were then validated in a new cohort of mice. Results As a potential top marker of disease, peptidase D was found at a higher ratio in Galphai2-/- mouse feces relative to controls (fold change 27; p = 0.019). Other proteins found to be enriched in Gαi2-/- mice were mainly pancreatic proteases, and proteins from plasma and blood cells. A tendency of increased calprotectin, subunit S100-A8, was also observed (fold change 21; p = 0.058). Proteases are potential activators of inflammation in the gastrointestinal tract through their interaction with the proteinase-activated receptor 2 (PAR2). Accordingly, the level of PAR2 was found to be elevated in both the colon and the pancreas of Galphai2-/- mice at different stages of disease. Conclusions These findings identify peptidase D, an ubiquitously expressed intracellular peptidase, as a potential novel marker of colitis. The elevated levels of fecal proteases may be involved in the pathogenesis of colitis and contribute to the clinical phenotype, possibly by activation of intestinal PAR2.

[1]  Degree of colitis correlates with microbial composition and cytokine responses in colon and caecum of Gαi2-deficient mice. , 2016, FEMS microbiology ecology.

[2]  Steven J Brown,et al.  Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. , 2015, Gastroenterology.

[3]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[4]  María Martín,et al.  UniProt: A hub for protein information , 2015 .

[5]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[6]  P. Siersema,et al.  Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. , 2015, Journal of Crohn's & Colitis.

[7]  I. Carroll,et al.  Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications. , 2013, World journal of gastroenterology.

[8]  Joshua E. Elias,et al.  Host-centric Proteomics of Stool: A Novel Strategy Focused on intestinal Responses to the Gut Microbiota* , 2013, Molecular & Cellular Proteomics.

[9]  A. Kumawat,et al.  Interplay between T(h)1 and T(h)17 effector T-cell pathways in the pathogenesis of spontaneous colitis and colon cancer in the Gαi2-deficient mouse. , 2013, International immunology.

[10]  S. Vermeire,et al.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. , 2012, Journal of Crohn's & colitis.

[11]  Brandi L. Cantarel,et al.  Integrated Metagenomics/Metaproteomics Reveals Human Host-Microbiota Signatures of Crohn's Disease , 2012, PloS one.

[12]  Ligong Liu,et al.  Antagonism of Protease-Activated Receptor 2 Protects against Experimental Colitis , 2012, Journal of Pharmacology and Experimental Therapeutics.

[13]  E. Karna,et al.  Thrombin-dependent modulation of β1-integrin-mediated signaling up-regulates prolidase and HIF-1α through p-FAK in colorectal cancer cells , 2011, Molecular and Cellular Biochemistry.

[14]  S. Raghavan,et al.  CD4+FoxP3+ Regulatory T Cells from Gαi2−/− Mice Are Functionally Active In Vitro, but Do Not Prevent Colitis , 2011, PloS one.

[15]  P. Andersen,et al.  Superoxide dismutase‐1 and other proteins in inclusions from transgenic amyotrophic lateral sclerosis model mice , 2010, Journal of neurochemistry.

[16]  A. Burgess,et al.  Murine fecal proteomics: a model system for the detection of potential biomarkers for colorectal cancer. , 2010, Journal of chromatography. A.

[17]  Å. Keita,et al.  Increased expression of protease-activated receptor-2 in mucosal mast cells in Crohn's ileitis. , 2009, Journal of Crohn's & colitis.

[18]  Adam Godzik,et al.  Shotgun metaproteomics of the human distal gut microbiota , 2008, The ISME Journal.

[19]  C. Eyers Universal sample preparation method for proteome analysis , 2009 .

[20]  M. Steinhoff,et al.  Protease-activated receptor-2 activation: a major actor in intestinal inflammation , 2008, Gut.

[21]  K. Søreide Proteinase-activated receptor 2 (PAR-2) in gastrointestinal and pancreatic pathophysiology, inflammation and neoplasia , 2008, Scandinavian journal of gastroenterology.

[22]  R. Willén,et al.  Transfer of Colitis by G&agr;i2‐deficient T Lymphocytes: Impact of Subpopulations and Tissue Origin , 2005, Inflammatory bowel diseases.

[23]  N. Vergnolle,et al.  CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT , 2005, Gut.

[24]  M. Oleksiewicz,et al.  Identification of stool proteins in C57BL/6J mice by two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry , 2005, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[25]  Young‐Mi Lee,et al.  Expression of Protease-Activated Receptor 2 in Ulcerative Colitis , 2003, Inflammatory bowel diseases.

[26]  J. Wallace,et al.  Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. , 2002, The American journal of pathology.

[27]  M. Nishida,et al.  Protease-activated receptor-2 (PAR-2) in the pancreas and parotid gland: Immunolocalization and involvement of nitric oxide in the evoked amylase secretion. , 2002, Life sciences.

[28]  L. Birnbaumer,et al.  Antibody response to dietary and autoantigens in Gαi2-deficient mice , 2001 .

[29]  L. Birnbaumer,et al.  Antibody response to dietary and autoantigens in G alpha i2-deficient mice. , 2001, European journal of gastroenterology & hepatology.

[30]  Harriman,et al.  Immune Activation in the Intestinal Mucosa Before the Onset of Colitis in Gαi2‐Deficient Mice , 2000, Scandinavian journal of immunology.

[31]  J. Phang,et al.  Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors , 1997, Journal of cellular biochemistry.

[32]  L. Birnbaumer,et al.  G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. , 1997, Journal of immunology.

[33]  A. Bradley,et al.  Ulcerative colitis and adenocarcinoma of the colon in Gαi2-deficient mice , 1995, Nature Genetics.

[34]  M. Bohe Pancreatic and granulocytic endoproteases in faecal extracts from patients with active ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.

[35]  S. H. Jackson,et al.  Iminodipeptiduria: a genetic defect in recycling collagen; a method for determining prolidase in erythrocytes. , 1975, Canadian Medical Association journal.